

For more information on the trials listed here, please call PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER. The PDQ Web site is accessible at www.cancer.gov/clinical_trials. A searchable Web site developed by the National Library of Medicine is also available at <http://clinicaltrials.gov>.

For information on trials being conducted at the H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, please visit www.MoffittCancerCenter.org/prevention_and_treatment/clinical_trials/.

Phase II

Combretastatin A₄ Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer
CWRU-ICC-2302, CASE-2302, NCT00060242

Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
MDA-2003-0308, NCT00085293, NCI-5954

FR901228 in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
MSKCC-04059, NCT00098813, NCI-6338

Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer
JHOC-J0459, JHOC-04080402, NCT00100828

Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
D4200C00008, NCT00098345

Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
MDA-2004-0059, NCT00104871, NCI-6132

17-AAG in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
MAYO-MC0476, NCI-6482, NCT00118248

Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
CASE-5304, NCT00126568, NCI-7037

Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma
UMCC 2003-044, NCT00115739, BUS168

Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
OSU-04110, NCT00134043, NCI-6902

Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer
IROF-019, NCT00124527

Phase I/II

Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A₄ Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer
CWRU-3302, CASE-3302, CWRU-040337, OXIGENE-CWRU-3302, NCT00077103

Phase I

FR901228 in Treating Patients With Refractory Thyroid Cancer or Other Advanced Cancer
NCI-03-C-0030, NCT00048334, NCI-5483

Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed by Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases
EORTC-11001, NCT00062348

No Phase Specified

Studies on Tumors of the Thyroid
770096, NCT00001160, 77-DK-0096

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer
UCSF-03201, GSK-UCSF-H28355-22994-01, UCSF-H28355-22994-01, NCT00098852

Evaluation Study of L-T3 Utility in the Follow-Up of Patients With Thyroid Cancer
CRC-03-52-R1, NCT00223158